| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AUTOLUS THERAPEUTICS PLC | 11 | Q2 2024 | 90.8% |
| ACHILLES THERAPEUTICS PLC | 11 | Q2 2024 | 53.1% |
| FREELINE THERAPEUTICS HLDGS | 9 | Q4 2023 | 27.4% |
| ADAPTIMMUNE THERAPEUTICS PLC | 9 | Q4 2023 | 4.9% |
| CENTURY THERAPEUTICS | 1 | Q2 2024 | 3.0% |
View Syncona Portfolio Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Freeline Therapeutics Holdings plc | February 22, 2024 | 65,872,764 | 100.0% |
| Achilles Therapeutics plc | February 13, 2024 | 11,086,909 | 27.2% |
| Autolus Therapeutics plc | February 13, 2024 | 33,527,162 | 14.4% |
| Freeline Therapeutics Holdings plc | March 25, 2022 | 37,862,147 | 62.3% |
| Nightstar Therapeutics plc | March 14, 2019 | 13,203,922 | 39.0% |
View Syncona Portfolio Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-23 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-02-22 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2024-02-01 |
| SC 13D/A | 2023-11-24 |
| 13F-HR | 2023-11-01 |
| SC 13D/A | 2023-10-18 |
View Syncona Portfolio Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.